Top

Diagnostic Pathology

Published in:

Open Access 01-12-2006 | Research

Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature

Authors: Masoud Mireskandari, Ali Fakhr Shafaii, Gian Kayser, Klaus Kayser

Published in: Diagnostic Pathology | Issue 1/2006

Abstract

Background

Gastric adenocarcinoma is one of the most frequent malignancies worldwide including Iran. This study was designed to immunohistochemically evaluate the CD117 and bcl-2 expression in gastric carcinomas and their potential use as therapeutic targets in the treatment of patients with advanced stage gastric cancer.

Materials and methods

Representative paraffin blocks obtained from 38 operated gastric adenocarcinoma patients were retrieved from Afzalipour Hospital pathology department archive, Kerman, Iran. Immunohistochemical analysis (IHC) for CD117 was carried out in all cases including negative (normal gastric epithelium) and positive (Gastrointestinal Stromal Tumor) controls. In addition, the cases were evaluated immunohistochemically for apoptosis-related protein (bcl-2), to evaluating a potential association of CD117 expression with the cell proliferation regulatory pathways.

Results

No positive reaction for CD117 was seen in gastric carcinoma tumor cells irrespective to the cell type, grade, and stage, proliferation and apoptosis rate. Expression of bcl-2 was observed in only one case.

Conclusion

We conclude that CD117 overexpression detectable by immunohistochemistry does not play a significant role in gastric carcinoma pathways and development, although overexpression at the gene level and/or mutated CD117 expression might exist. Thus, it is unlikely that the CD117 pathway is of clinical significance in gastric carcinoma patients.

Available only for authorised users

Akin C, Schwartz LB, Kitoh T, Obayoshi H, Worbec AS: Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis, relationship to disease severity and bone marrow pathology. Blood. 2000, 96: 1267-73.PubMed

Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A: Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer. 2003, 40: 173-80. 10.1016/S0169-5002(03)00034-5.CrossRefPubMed

Ashman KL: The biology of stem cell factor and its receptor c-kit. Int J Biol. 1999, 31: 1037-51.

Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Mester J, Gespach C.: The kit thyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002, 62: 4879-83.PubMed

Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005, 23: 2162-71. 10.1200/JCO.2005.01.014.CrossRefPubMed

Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, Rodech U: Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. J Cell Physiol. 1997, 172: 1-11. 10.1002/(SICI)1097-4652(199707)172:1<1::AID-JCP1>3.0.CO;2-S.CrossRefPubMed

Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ: Effects of imatinibe mesylate on neuroblastoma tumorgenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 2004, 96: 46-55.CrossRefPubMed

Blanke CD, Coia LR, Schwarz RE, Bonin SR: Gastric cancer management. Cancer management: a multidisciplinary approach. Edited by: Richard Pazdur, William J Hoskins, Lawrence R Coia, Lawrence D Wagman. 2005, CMP Healthcare Media, 279-9

Camirand A, Pollak M: Co-targeting IGF-1R and c-kit: synergistic inhibition proliferation and induction of apoptosis, in H 209 small lung cancer cells. Br J Cancer. 2004, 90: 1825-9.PubMedCentralPubMed

10.

Canonico B, Felici C, Papa S: CD117. J Biol Regul Homeost Agents. 2001, 15: 90-4.PubMed

11.

Chen XL, Su BS, Sun RQ, Zhang J, Wang YL: Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma. World J Gastroenterol. 2005, 11: 1228-1231.PubMedCentralCrossRefPubMed

12.

de Jong FA, Verweij J: Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. Expert Rev Anticancer Ther. 2003, 3: 757-66. 10.1586/14737140.3.6.757.CrossRefPubMed

13.

Feng HL, Sawndlow JI, Sporks AE, Sandra A: Deacreased level of the c-kit receptor is associated with increased apoptosis in subfertile human testes. Fertility and Sterility. 1999, 71: 85-9. 10.1016/S0015-0282(98)00401-4.CrossRefPubMed

14.

Forones NM, Carvalho AP, Giannotti-Filho O, Lourenco LG, Oshima CT: Cell proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq Gastroenterl. 2005, 42: 30-4.CrossRef

15.

Fricke E, Keller G, Becker I, Rosivatz E, Schott C, Plaschke S, Rudelius M, Hermannstadter C, Busch R, Hofler H, Becker KF, Luber B: Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. Int J Cancer. 2003, 10: 60-5. 10.1002/ijc.10879.CrossRef

16.

Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL, Gaboli M, Sierrasesumaga L, Martin-Algarra S, Pardo J, Prosper F, de Alava E: Imatinib inhibits proliferation of Ewing sarcoma tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res. 2004, 10: 751-61. 10.1158/1078-0432.CCR-0778-03.CrossRefPubMed

17.

Hamel W, Westphal M: The road less traveled: c-kit and stem cell factor. J Neurooncol. 1997, 35: 327-33. 10.1023/A:1005828921273.CrossRefPubMed

18.

Hassan S, Kinoshita Y, Kawaname C, Hishik O, Fanaska C: Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci. 1998, 35: 327-33.

19.

Higashiyama M, Monden T, Ogawa M, Matsuura N, Murotani M, Kawasaki Y, Tomita N, Murata A, Shimano T, Mori T: Immunohistochemical study on pancreatic secretory trypsin inhibitor (PSTI) in gastric carcinomas. Am J Clin Pathol. 1990, 93: 8-13.PubMed

20.

Hines SJ, Organ C, Kornstein MJ, Krystal JW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ. 1995, 6: 769-79.PubMed

21.

Hornick JL, Fletcher CDM: Immunohistochemical staining for c-kit (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002, 117: 188-93. 10.1309/LX9U-F7P0-UWDH-8Y6R.CrossRefPubMed

22.

Immunohistochemistry Literature Database Query System. [http://www.immunoquery.com/]

23.

Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005, 65: 264-76.PubMed

24.

Jiang X, Gurel O, Mendiaz EA, Stearns GW, Clogston CL, Lu HS, Osslund TD, Syed RS, Langley KE, Hendrickson WA: Structure of active core of human stem cell factor and analysis of binding to its receptor kit. EMBO J. 2000, 19: 3192-203. 10.1093/emboj/19.13.3192.PubMedCentralCrossRefPubMed

25.

Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC: kit mutations are common in testicular seminomas. Am J Pathol. 2004, 164: 305-13.PubMedCentralCrossRefPubMed

26.

Kim R, Emi M, Matsuura K, Tanabe K: Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma. Gan To Kagaku Ryoho. 2005, 32: 1540-5.PubMed

27.

Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick CJ, Theobald M, Gschaidmeier H, Huber C, Fischer T: Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood. 2004, 103: 3644-54. 10.1182/blood-2003-06-2071.CrossRefPubMed

28.

Lahm H, Amstad P, Yilmaz A, Borbenyi Z, Wyniger J, Fischer JR, Suardet L, Givel JC, Odartchenko N: Interlukin 4 down-regulates expression of c-kit and stem cell factor in human colorectal carcinoma cells. Cell Growth Differ. 1995, 6: 1111-8.PubMed

29.

Lauren F: The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt to histoclinical classification. Acta Pathol Microbiol Scand. 1995, 64: 31-40.

30.

Levesque JP, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ: Granulocyte colony stimulating factor induces the release in the bone marrow of proteases that cleave c-kit receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol. 2003, 31: 109-17. 10.1016/S0301-472X(02)01028-7.CrossRefPubMed

31.

Liu HF, Liu WW, Wang GA, Teng XC: Effect of Helicobacter pylori infection on Bax protein expression in patients with gastric precancerous lesions. World J Gastroenterol. 2005, 11: 5899-5901.PubMedCentralCrossRefPubMed

32.

Liu W, Guo QL, You QD, Zhao L, Gu HY, Yuan ST: Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol. 2005, 11: 3655-3659.PubMedCentralCrossRefPubMed

33.

Matsui J, Wakabayashi T, Asoda M, Yoshimatsuk O: Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem. 2004, 279: 186-7.

34.

Miettinen M: New challenges in the identification of gastrointestinal stromal tumors and other possible KIT-deriven tumors. Am J Clin Pathol. 2002, 117: 183-185. 10.1309/DEV8-2HTW-PN6Q-DYWH.CrossRefPubMed

35.

Nakamura Y, Tajima F, Ishiga K, Yamazaki H, Oshimura M, Shiota G, Murawaki Y: Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol. 2004, 32: 390-6. 10.1016/j.exphem.2004.01.004.CrossRefPubMed

36.

Nakatani T, Marui T, Yamamoto T, Hitora T, Akisue T, Kawamoto T, Nagira K, Fujita I, Matsumoto K, Yoshiya S, Kurosaka M: Expression of stem cell factor and c-kit in human malignant fibrous histiocytoma cell line (TNMY1). Anticancer Res. 23: 2329-33.

37.

Nishida K, Tsukamoto T, Uchida K, Takahashi T, Takahashi T, Ueda R: Introduction of the c-kit gene leads to growth suppression of breast cancer cell line, MCF-7. Anticancer Res. 1996, 16: 3397-402.PubMed

38.

Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T: Successful treatment of hepatocellular carcinoma with thyrosine kinase inhibitor imatinib mesylate in a patient with liver cirrhosis. Anticancer Drugs. 2004, 15: 405-9. 10.1097/00001813-200404000-00014.CrossRefPubMed

39.

Raspollini MR, Paglierani M, Taddei GL, Villanucci A, Amunni G, Taddei A: The protooncogene c-kit is expressed in leiomyosarcoma of the uterus. Gynecol Oncol. 2003, 93: 718-10.1016/j.ygyno.2004.03.017.CrossRef

40.

Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D: Immunohistochemical staining for c-kit (CD117) is a rare event in colorectal carcinoma. Comment in J Clin Oncol. 2003, 21: 3885-6. discussion 3887-9CrossRef

41.

Reedy MV, Johnson RL, Erickson CA: The expression patterns of c-kit and SI in chicken embryos suggest unexpected role for these agents in somite and limb development. Gene Expression Patterns. 2003, 3: 53-58. 10.1016/S1567-133X(02)00072-8.CrossRefPubMed

42.

Romagnoli S, Graziani D, Bramerio M, Gambacorta M, Colombo P, Roncalli M, Coggi G, Bosari S: Imunohistochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pathol Res Pract. 2005, 201: 71-81. 10.1016/j.prp.2005.01.005.CrossRefPubMed

43.

Rosai J, Ed: Ackerman's Surgical Pathology. 2004, St. Louis: Mosby, 9

44.

Sandberg AA, Bridge JA: Updates on cytogenetics and molecular genetics of bone and soft tissue tumors, gastrointestinal stromal tumors. Cancer Genet Cytogenet. 2002, 135: 1-22. 10.1016/S0165-4608(02)00546-0.CrossRefPubMed

45.

Spiekermann K, Faber F, Voswinckel R, Hiddemann W: The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol. 2002, 30: 767-73. 10.1016/S0301-472X(02)00837-8.CrossRefPubMed

46.

Surgical Oncology Net. [http://www.surgical-oncology.net]

47.

Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E: Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci. 2002, 47: 107-13. 10.1023/A:1013223722331.CrossRefPubMed

48.

Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, Krystal GW: The insulin-like growth factor 1 (IGF-1) receptor kinase inhibitor NVP-ADW742 in combination with STI571 decline spectrum of dependence of small cell lung cancer on IGF-stem cell factor signaling. Mol Cancer Ther. 2004, 3: 527-35.PubMed

49.

Watanabe H, Tokuyama H, Ohta H, Satomura Y, Okai T, Ooi A, Mai M, Sawabu N: Expression of placental alkaline phosphatase in gastric and colorectal cancers. An immunohistochemical study using the prepared monoclonal antibody. Cancer. 1990, 66 (12): 2575-82.CrossRefPubMed

50.

Xia HH, Talley NJ: Apoptosis in gastric epithelium induced by helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol. 2001, 96: 16-26. 10.1016/S0002-9270(00)02240-1.CrossRefPubMed

51.

Yamamoto T, Nakatani T, Marui T, Akisue T, Fujita I, Matsumoto K, Hitora T, Kawamoto T, Nagira K, Kurosaka M: Expression of stem cell factor and lack of c-kit expression in malignant fibrous histiocytoma of soft tissue. Anticancer Res. 2003, 23: 4305-8.PubMed

Title: Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature
Authors: Masoud Mireskandari
Ali Fakhr Shafaii
Gian Kayser
Klaus Kayser
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2006
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/1746-1596-1-7

At a glance: The STEP trials

Springer Medicine

Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature

Abstract

Background

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2006

Immunohistochemical localization patterns for vimentin and other intermediate filaments in calcified ovarian fibrothecoma

Melanosis intestini: case report

Malignancy in the blind painful eye – report of two cases and literature review

Dysplastic Ichthyosis Uteri-like changes of the entire endometrium associated with a squamous cell carcinoma of the uterine cervix

Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary

Uncommon sarcomas of the uterine cervix: a review of selected entities